Mannose treatment impedes the production of lactate by targeting HK2 in colorectal cancer cells and downregulates markers of the M2-like phenotype of macrophages, such as VEGF, arginase 1 (Arg-1), HIF-1α, and Cluster of Differentiation 206 (CD206), thereby disrupting the tumor-promoting microenvironment. The gene discussed is HIF1A; the disease is colorectal cancer.